Otsuka Pharmaceutical
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 13 disclosed transactions, Otsuka Pharmaceutical concentrates its licensing activity in Immunology, Neurology, and Cardiovascular. Otsuka Pharmaceutical pays a 0.70x discount to market median. Their most common deal structure is License, with an average disclosed value of $547M. Most recent activity: 2026.
Pipeline coverage & gaps
Otsuka Pharmaceutical has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 7 | $79M | $425M |
| Acquisition | 4 | $575M | $882M |
| Collaboration | 2 | $55M | $305M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | TSND-201 (methylone) | Transcend Therapeutics | depression | unknown | $700M | $1.2B |
| 2025 | 4D-150 | 4D Molecular Therapeutics | retinal vascular disease | phase_3 | $85M | $471M |
| 2025 | CAN10 | Cantargia AB | hidradenitis suppurativa | phase_1 | $33M | $613M |
| 2025 | CAN10 | Cantargia AB | hidradenitis suppurativa | phase_1 | $33M | $613M |
| 2024 | pku | Jnana Therapeutics | pku | phase_2 | $800M | $1.1B |
| 2024 | Jnana Therapeutics (JNT-517 PKU program + RAPID platform) | Jnana Therapeutics | phenylketonuria (PKU) | unknown | $800M | $1.1B |
| 2024 | PD-1 agonist | iBio, Inc. | autoimmune | preclinical | $1M | $54M |
| 2021 | ulotaront (SEP-363856), SEP-4199, SEP-378614, SEP-380135 | Sunovion Pharmaceuticals | CNS / neuropsychiatric disorders including possible bipolar disorder | unknown | $270M | $890M |
| 2021 | PCN-101 (R-ketamine) | Perception Neuroscience (atai Life Sciences) | major depressive disorder (MDD) / treatment-resistant depression (TRD) | phase_2 | $20M | $141M |
| 2020 | voclosporin | Aurinia Pharmaceuticals Inc. | lupus nephritis | phase_3 | $50M | $100M |
| 2020 | Voclosporin | Aurinia Pharmaceuticals | lupus nephritis | phase_3 | $50M | $100M |
| 2020 | NEXLETOL / NEXLIZET | Esperion Therapeutics | hypercholesterolemia | approved | $60M | $510M |
| 2020 | NEXLETOL/NEXLIZET | Esperion Therapeutics, Inc. | hypercholesterolemia and familial hypercholesterolemia | approved | $60M | $150M |
How this is computed
For each Otsuka Pharmaceutical deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.442, clamped to [0.7, 1.5].